

# Leizhen Zheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7807717/publications.pdf>

Version: 2024-02-01

15  
papers

1,002  
citations

933447

10  
h-index

1058476

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1489  
citing authors

#	ARTICLE	IF	CITATIONS
1	GPR120 induces regulatory dendritic cells by inhibiting HK2-dependent glycolysis to alleviate fulminant hepatic failure. <i>Cell Death and Disease</i> , 2022, 13, 1.	6.3	45
2	Distinct genomic profile in h. pylori associated gastric cancer. <i>Cancer Medicine</i> , 2021, 10, 2461-2469.	2.8	8
3	Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 6397-6410.	1.9	13
4	Prognostic value and association of Lauren classification with VEGF and VEGFR2 expression in gastric cancer. <i>Oncology Letters</i> , 2019, 18, 4891-4899.	1.8	17
5	The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer. <i>Cancer Biology and Therapy</i> , 2019, 20, 497-504.	3.4	13
6	Genetic Variants Within MTORC1 Genes Predict Gastric Cancer Prognosis in Chinese Populations. <i>Journal of Cancer</i> , 2018, 9, 1448-1454.	2.5	5
7	Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model. <i>Blood</i> , 2018, 132, 2050-2050.	1.4	1
8	Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 153.	17.0	70
9	Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib. <i>Journal of Clinical Oncology</i> , 2017, 35, 4052-4052.	1.6	0
10	A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 4017-4024.	1.8	14
11	Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2016, 14, 38.	1.9	15
12	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1448-1454.	1.6	756
13	Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. <i>American Journal of Cancer Research</i> , 2016, 6, 84-90.	1.4	8
14	Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 12084-92.	0.5	27
15	A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. <i>Experimental and Therapeutic Medicine</i> , 0, , .	1.8	0